your badges 52W Range $16–$110 82% of range Analyst Rating STRONG BUY 23 analysts Price Target $120 +29% upside P/E 29.1 ROE -26.5% Net Profit Margin ·

SYRE Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range

03
Price $93.19
Market Cap (MRQ) $8.21B
P/E 29.1
EPS $13.76
Revenue $0
ROE -26.5%
52W Range $16–$110

SYRE Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view

04
range
bars

Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.

Stock splits 1
Ex-date Split Type
Sept. 8, 2023 1-for-25 Reverse

About Spyre Therapeutics, Inc. - Common Stock Company overview from Wikipedia

05 · wikidata
sectorHealthcare industryBiotechnology employees125 countryUS

10-Year Performance Revenue, net income, margins and EPS trends

06
Revenue$0
2016-12-31 → 2025-12-31
EPS$13.76
2020-12-31 → 2023-12-31
Free Cash Flow·
2016-12-31 → 2024-12-31
Net margin·
2018-12-31 → 2023-12-31
Valuation & Ratios 07–12

Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?

Metric 5Y trend SYRE 5Y avg Peer Median Verdict
P/E 29.15Y avg ≈2.7 ≈2.7 · ·
P/B (MRQ) 7.55Y avg ≈22.7 ≈22.7 7.1 Fair value
Price / Cash Flow -43.45Y avg ≈-35.6 ≈-35.6 · ·
Price / Tangible Book 10.35Y avg ≈19.0 ≈19.0 · ·

Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.

value · ≈ 5Y avg · industry median · verdict relative to median

Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date

14
Avg Surprise 27.7%
Next Report Nov 02, 2026
PeriodReportEPS ActualEPS EstSurprise
June 30, 2026 Aug 3, 2026 $-0.36 $-0.77 53.5%
March 31, 2026 May 7, 2026 $-0.74 $-0.68 -8.9%
Dec. 31, 2025 $-0.70 $-0.79 11.4%
Sept. 30, 2025 $-0.15 $-0.76 80.3%
June 30, 2025 $-0.77 $-0.77 -0.17%
March 31, 2025 $-0.60 $-0.86 30.1%

Full Fundamentals All metrics by year — income statement, balance sheet, cash flow

15
Income Statement 14
Metric Trend 2025202420232022202120202019201820172016
Revenue $0$0$886.0K$2M$19M$0$0$4M$5M$5M
R&D Expense ···$59M$57M$60M$65M$37M$23M$18M
SG&A Expense $48M$46M$40M$29M$27M$22M$16M$13M$10M$8M
Operating Expenses $210M$209M$243M$87M$84M$81M$80M$49M$33M$27M
Operating Income $-210M$-209M$-242M$-85M$-66M$-81M$-80M$-45M$-28M$-22M
Other Non-op $29M$-21M$-19M$-7.0K$-122.0K$-5.0K$-63.0K$-57.0K$-42.0K$-36.0K
Pretax Income $-155M$-208M$-339M$-84M$-66M$-81M$-78M···
Income Tax $-15.0K$51.0K$-26.0K$-136.0K$141.0K$0$0$0$0$0
Net Income $-155M$-208M$-339M$-84M$-66M$-81M$-78M$-44M$-27M$-22M
EPS (Basic) ··$13.76$-24.86$-25.02$-1.52····
EPS (Diluted) ··$13.76$-24.86$-25.02$-1.52····
Shares (Basic) ··6,897,0653,371,2312,629,78453,371,730····
Shares (Diluted) ··6,897,0653,371,2312,629,78453,371,730····
EBITDA $-210M$-209M$-242M$-83M$-64M$-80M$-80M$-45M$-27M$-22M
Balance Sheet 21
Metric Trend 2025202420232022202120202019201820172016
Cash & Equivalents $86M$89M$189M$35M$15M$90M$19M$22M$13M$48M
Short-term Investments ·······$52M$37M$16M
Prepaid Expense $21M$5M$2M$6M$5M$4M$3M$2M$2M$2M
Current Assets $778M$608M$342M$62M$99M$150M$75M$77M$55M$66M
PP&E (Net) ··$0$3M$5M$6M$2M$1M$854.0K$599.0K
PP&E (Gross) ··$0$7M$7M$8M$3M$2M$1M$839.0K
Accum. Depreciation ··$0$4M$3M$2M$1M$752.0K$487.0K$240.0K
Other Non-current Assets $0$10.0K$9.0K$683.0K$842.0K$115.0K$67.0K$50.0K$232.0K$40.0K
Total Assets $778M$608M$342M$71M$110M$162M$83M$78M$56M$67M
Accounts Payable ···$677.0K$3M$2M$3M$663.0K$389.0K$168.0K
Current Liabilities $59M$54M$32M$15M$20M$16M$18M$10M$6M$4M
Capital Leases ··$0$4M$5M$5M$5M···
Other Non-current Liabilities $0··$0$16.0K$214.0K$31.0K$72.0K$111.0K$132.0K
Total Liabilities $63M$91M$73M$21M$26M$22M$23M$10M$6M$4M
Common Stock $15.0K$13.0K$10.0K$6.0K$5.0K$5.0K$3.0K$2.0K$2.0K$1.0K
Paid-in Capital ·······$184M$123M$108M
Retained Earnings $-1.13B$-972M$-764M$-426M$-342M$-276M$-195M$-117M$-73M$-45M
AOCI $869.0K$180.0K$302.0K$-48.0K$-20.0K$11.0K$51.0K$-27.0K$-102.0K$-4.0K
Stockholders' Equity $715M$518M$184M$50M$84M$140M$60M$67M$50M$63M
Liabilities + Equity $778M$608M$342M$71M$110M$162M$83M$78M$56M$67M
Shares Outstanding 78,189,81160,257,00036,057,0002,614,0001,974,0001,918,00029,084,43724,140,09716,670,18813,430,833
Cash Flow 12
Metric Trend 2025202420232022202120202019201820172016
D&A $0$0$744.0K$2M$2M$996.0K$418.0K$293.0K$249.0K$132.0K
Stock-based Comp $38M$45M$26M$7M$8M$6M$5M$4M$2M$1M
Other Non-cash $-52M$6M$212M$-5M$2M$-2M$7M$8M$-120.0K$2M
Operating Cash Flow $-169M$-157M$-100M$-80M$-54M$-76M$-66M$-32M$-25M$-19M
CapEx ·$0$0$38.0K$573.0K$4M$1M$422.0K$619.0K$212.0K
Investing Cash Flow $-143M$-353M$-108M$57M$-23M$-8M$-2M$-15M$-23M$-12M
Stock Issued ··$85M$0$0·····
Net Stock Activity ··$85M·······
Financing Cash Flow $309M$411M$361M$43M$1M$155M$66M$57M$12M$49M
Net Change in Cash $-4M$-100M$153M$19M$-75M$71M$-2M$10M$-35M$18M
Taxes Paid $-15.0K·········
Free Cash Flow ·$-157M$-100M$-80M$-54M$-80M$-67M$-33M$-25M$-19M
Profitability 7
Metric Trend 2025202420232022202120202019201820172016
Operating Margin ··-27348.0%-3640.2%-350.3%··-1169.3%··
Net Margin ··-38238.2%-3598.7%-351.1%··-1140.6%··
Pretax Margin ··-38241.1%-3604.6%-350.4%·····
EBITDA Margin ··-27264.0%-3573.0%-341.9%··-1161.8%··
ROA -22.4%-43.8%·-92.6%-48.5%-66.1%-97.3%-66.3%-44.2%-41.0%
ROE -26.5%-49.2%·-142.2%-70.8%-58.6%-111.9%-67.7%-48.1%-106.5%
ROIC -29.3%-40.3%·-168.3%-78.4%·····
Liquidity & Solvency 2
Metric Trend 2025202420232022202120202019201820172016
Current Ratio 13.311.3·4.24.99.14.17.59.816.8
Quick Ratio 1.51.7·2.40.85.51.07.38.916.0
Efficiency 1
Metric Trend 2025202420232022202120202019201820172016
Asset Turnover 0.00.0·0.00.10.00.00.1··
Per Share 5
Metric Trend 2025202420232022202120202019201820172016
Book Value / Share $9.15$8.59·$0.77$1.70$2.92$2.07$2.79$3.02$4.69
Revenue / Share ··$0.13$0.03······
Cash Flow / Share ··$-14.49$-0.95······
Cash / Share $1.10$1.48·$0.53$0.31$1.88$0.66$0.93$0.77$3.56
EPS (TTM) $3.23$3.23$13.76$-24.86$-25.02$-1.52····
Growth Rates 1
Metric Trend 2025202420232022202120202019201820172016
Revenue YoY ··-62.0%-87.6%······
Valuation (TTM) 10
Metric Trend 2025202420232022202120202019201820172016
Revenue TTM $0$0$886.0K$2M$19M$0$0$4M$5M$5M
Net Income TTM $-155M$-208M$-339M$-84M$-66M$-81M$-78M$-44M$-27M$-22M
Market Cap $2.56B$1.40B·$735M$5.86B$9.44B$5.56B$4.52B$2.25B$1.46B
P/E 10.17.21.6-0.5-4.7-129.4····
P/S ···315.7312.8··1162.6433.2315.6
P/B 3.62.7·14.669.867.592.567.044.823.2
P / Tangible Book 3.62.74.214.669.867.5····
P / Cash Flow -15.1-8.9·-9.2-109.1-124.5-84.6-140.4-91.6-77.5
P / FCF ·-8.9·-9.2-108.0-117.9-82.7-138.6-89.3-76.7
Earnings Yield 9.9%13.9%63.9%-221.0%-21.1%-0.77%····

Most recent period on the left · null values shown as ·

Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years

16
Metric 2025-12-312024-12-312023-12-312022-12-312021-12-31
Revenue $0 $0 $886.0K $2M $19M
Operating Margin % · · -27348.0% -3640.2% -350.3%
Net Income $-155M $-208M $-339M $-84M $-66M
Diluted EPS · · $13.76 $-24.86 $-25.02

Institutional owners (13F) 277 filers · $8.3B total · As of June 30, 2026

17

Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.

Holders 277
Value held $8.3B
New positions 94
Exited positions 21
Institutional activity — Q2 2026 vs prior quarter
New positions Exited positions Increased Decreased Net shares change
94 (+34 vs prior Q) 21 (+10 vs prior Q) 105 (+38 vs prior Q) 56 (+8 vs prior Q) +11.3M

Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.

Institution Value Shares % of tracked 13F Type
FMR LLC $1,156,464,882 13,026,187 13.95% Shares
BlackRock, Inc. $577,656,391 6,506,605 6.97% Shares
PERCEPTIVE ADVISORS LLC $383,484,855 4,319,496 4.63% Shares
RTW INVESTMENTS, LP $377,492,205 4,251,996 4.55% Shares
Paradigm Biocapital Advisors LP $340,984,271 3,840,778 4.11% Shares
VANGUARD CAPITAL MANAGEMENT LLC $306,173,899 3,448,681 3.69% Shares
STATE STREET CORP $271,437,392 3,057,416 3.27% Shares
Venrock Adviser, LLC $265,048,073 2,985,448 3.20% Shares
Driehaus Capital Management LLC $248,509,957 2,799,166 3.00% Shares
GEODE CAPITAL MANAGEMENT, LLC $239,258,122 2,562,265 2.89% Shares
VANGUARD PORTFOLIO MANAGEMENT LLC $206,866,100 2,330,098 2.50% Shares
Capital World Investors $205,574,795 2,315,553 2.48% Shares
TCG Crossover Management, LLC $168,733,670 1,900,582 2.04% Shares
TANG CAPITAL MANAGEMENT LLC $167,989,516 1,892,200 2.03% Shares
BANK OF AMERICA CORP /DE/ $157,837,878 1,777,854 1.90% Shares
ADAGE CAPITAL PARTNERS GP, L.L.C. $152,905,794 1,722,300 1.84% Shares
WELLINGTON MANAGEMENT GROUP LLP $140,406,014 1,581,505 1.69% Shares
VANGUARD GROUP INC $132,189,024 4,035,074 1.59% Shares
GOLDMAN SACHS GROUP INC $131,222,079 1,478,059 1.58% Shares
FRANKLIN RESOURCES INC $130,767,861 1,472,943 1.58% Shares
Remedium Capital Partners, LLC $129,988,924 1,464,169 1.57% Shares
Affinity Asset Advisors, LLC $113,561,517 1,279,134 1.37% Shares
JPMORGAN CHASE & CO $98,870,628 1,093,026 1.19% Shares
Holocene Advisors, LP $90,126,793 1,015,170 1.09% Shares
MARSHALL WACE, LLP $88,042,506 991,693 1.06% Shares
Polar Capital Holdings Plc $87,715,439 988,009 1.06% Shares
Siren, L.L.C. $85,992,130 968,598 1.04% Shares
Capital International Investors $84,802,301 955,196 1.02% Shares
JANUS HENDERSON GROUP PLC $83,586,597 1,656,164 1.01% Shares
BRAIDWELL LP $78,079,080 879,467 0.94% Shares
Commodore Capital LP $75,177,661 846,786 0.91% Shares
UBS Group AG $74,847,843 843,071 0.90% Shares
NORTHERN TRUST CORP $59,884,685 674,529 0.72% Shares
CHARLES SCHWAB INVESTMENT MANAGEMENT INC $57,969,611 652,958 0.70% Shares
Pictet Asset Management Holding SA $55,766,092 628,138 0.67% Shares
EMERALD ADVISERS, LLC $50,376,435 567,430 0.61% Shares
VICTORY CAPITAL MANAGEMENT INC $49,182,345 553,980 0.59% Shares
VANGUARD FIDUCIARY TRUST CO $48,952,315 551,389 0.59% Shares
Candriam S.C.A. $48,454,915 546,312 0.58% Shares
MORGAN STANLEY $44,386,718 499,963 0.54% Shares
VOYA INVESTMENT MANAGEMENT LLC $38,325,793 431,694 0.46% Shares
EMERALD MUTUAL FUND ADVISERS TRUST $35,624,839 401,271 0.43% Shares
SAMLYN CAPITAL, LLC $35,518,659 400,075 0.43% Shares
AMERIPRISE FINANCIAL INC $31,612,960 356,082 0.38% Shares
Integral Health Asset Management, LLC $28,853,500 325,000 0.35% Shares
Woodline Partners LP $27,171,030 306,049 0.33% Shares
JENNISON ASSOCIATES LLC $26,916,321 303,180 0.32% Shares
ADAR1 Capital Management, LLC $25,211,922 283,982 0.30% Shares
BNP PARIBAS FINANCIAL MARKETS $23,075,964 259,923 0.28% Shares
Bank of New York Mellon Corp $21,768,235 245,193 0.26% Shares

Show all 277 institutional owners →

Activists & 5%+ owners 2 positions

18

Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.

Filer Filed Stake Status Purpose Filing
Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Peter Evan Harwin, Tomas Kiselak ×8 filings June 23, 2026 9.99% Amendment Board campaign SEC
Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Felix J. Baker, Julian C. Baker ×3 filings Feb. 10, 2022 · Initial filing Board campaign SEC

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Company insiders 37 insiders · 21 officers · 19 directors

19
Insider Role Last activity Shares owned Buys 12m Sells 12m Net 12m
Cameron Turtle Chief Executive Officer Oct. 1, 2026 S 537,540 0 40 $-11,374,650
Jeff Marc Goldberg President and CEO Nov. 29, 2022 A · 0 0 $0
Anthony G. Quinn President & CEO March 16, 2022 P 550,540 0 0 $0
David George Lowe CEO and President March 20, 2017 A 5,658 0 0 $0
Scott L Burrows Chief Financial Officer Oct. 1, 2026 M 79,762 0 26 $-9,124,219
Jonathan Alspaugh President and CFO June 22, 2023 A 165,372 0 0 $0
Charles N York II Chief Financial Officer and VP Feb. 14, 2020 A 34,787 0 0 $0
Leslie Sloan Chief Operating Officer Aug. 23, 2022 A · 0 0 $0
Heidy King-Jones Chief Legal Officer and Corporate Secretary Oct. 1, 2026 M 2,845 0 10 $-5,114,431
Sheldon Sloan Chief Medical Officer July 1, 2026 M 0 0 11 $-7,354,471
Linda L Neuman Chief Medical Officer Feb. 23, 2023 A · 0 0 $0
James Paul Kastenmayer General Counsel Feb. 23, 2023 A · 0 0 $0
Jr. Michael Conick Hanley Chief Business Officer Feb. 23, 2023 A 36,200 0 0 $0
Steven Weber VP, Controller&Princ Acctg Off Feb. 17, 2022 A · 0 0 $0
Madduri Ravin Rao Chief Medical Officer Feb. 14, 2020 A · 0 0 $0
James Wooldridge Chief Medical Officer Feb. 28, 2019 A · 0 0 $0
Aaron Schuchart Chief Business Officer Feb. 28, 2019 A 2,500 0 0 $0
Scott W Rowlinson VP, Research Aug. 22, 2017 A 11,204 0 0 $0
Joseph E Tyler VP, Manufacturing Aug. 22, 2017 A 42,428 0 0 $0
Henry Hebel VP, Product Development March 20, 2017 A · 0 0 $0
Sandra Rojas-Caro Chief Medical Officer May 17, 2016 A · 0 0 $0
Jeffrey W. Albers Director Aug. 7, 2026 M 9,360 0 3 $-2,404,190
Michael Thomas Henderson Director June 22, 2026 S 68,606 0 5 $-7,952,050
Sandra Milligan Director May 27, 2026 A · 0 0 $0
Mark C. Mckenna Director May 27, 2026 A · 0 0 $0
Laurie Stelzer Director May 27, 2026 A · 0 0 $0
Hunter C Smith Director June 22, 2023 A · 0 0 $0
Alison Frances Lawton Director June 22, 2023 A · 0 0 $0
Russell J. Cox Director June 22, 2023 A 7,000 0 0 $0
Ivana Magovcevic-Liebisch Director June 22, 2023 A · 0 0 $0
Marcio Souza Director Aug. 25, 2022 P 90,000 0 0 $0
Armen Shanafelt Director June 7, 2022 A 150,000 0 0 $0
Sandesh Mahatme Director June 7, 2022 A · 0 0 $0
Bryan V Lawlis Director June 7, 2022 A · 0 0 $0
Suzanne Louise Bruhn Director June 8, 2020 A · 0 0 $0
George Georgiou Director Aug. 13, 2018 M 175,861 0 0 $0
Eli Lilly and Company 10% owner April 12, 2016 C 2,568,543 0 0 $0

Insiders from SEC Form 3/4/5 filings; net = open-market P/S only

ETF ownership Held by 36 ETFs

20

Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.

Fund Weight Units As of Source
LABU · Direxion Shares ETF Trust 0.89% 44,942 NS July 31, 2026 N-PORT
BBC · ETFis Series Trust I 0.82% 3,847 NS July 31, 2026 N-PORT
JDOC · J.P. Morgan Exchange-Traded Fund Tr… 0.77% 710 NS July 31, 2026 N-PORT
DWAS · Invesco Exchange-Traded Fund Trust … 0.75% 33,756 SH Oct. 2, 2026 Daily
FDMO · FIDELITY COVINGTON TRUST 0.70% 64,674 NS July 31, 2026 N-PORT
ESSC · Strategy Shares 0.55% 2,023 NS July 31, 2026 N-PORT
IBBQ · Invesco Exchange-Traded Fund Trust … 0.53% 6,226 SH Oct. 2, 2026 Daily
IBB · iShares Trust 0.51% 591,167 SH Sept. 11, 2026 Daily
IWO · iShares Trust 0.43% 700,908 SH Sept. 11, 2026 Daily
VTWG · VANGUARD SCOTTSDALE FUNDS 0.39% 79,707 SH Aug. 19, 2026 Daily
BBSC · J.P. Morgan Exchange-Traded Fund Tr… 0.30% 20,972 NS July 31, 2026 N-PORT
BKSE · BNY Mellon ETF Trust 0.28% 2,523 NS July 31, 2026 N-PORT
PWS · Pacer Funds Trust 0.25% 614 NS July 31, 2026 N-PORT
RSSL · Global X Funds 0.24% 35,657 NS July 31, 2026 N-PORT
IWM · iShares Trust 0.22% 1,903,999 SH Sept. 11, 2026 Daily
VTWO · VANGUARD SCOTTSDALE FUNDS 0.20% 428,619 SH Aug. 19, 2026 Daily
VFMO · VANGUARD WELLINGTON FUND 0.18% 39,684 SH Aug. 19, 2026 Daily
ESML · iShares Trust 0.09% 29,173 SH Sept. 11, 2026 Daily
ISCG · iShares Trust 0.08% 8,816 SH Sept. 11, 2026 Daily
VXF · VANGUARD INDEX FUNDS 0.08% 886,783 SH Aug. 19, 2026 Daily
FHLC · FIDELITY COVINGTON TRUST 0.08% 26,643 NS July 31, 2026 N-PORT
VBR · VANGUARD INDEX FUNDS 0.07% 568,910 SH Aug. 19, 2026 Daily
VHT · VANGUARD WORLD FUND 0.07% 168,446 SH Aug. 19, 2026 Daily
PRFZ · Invesco Exchange-Traded Fund Trust 0.06% 17,397 SH Oct. 2, 2026 Daily
WSML · iShares Trust 0.05% 3,911 SH Sept. 11, 2026 Daily
VB · VANGUARD INDEX FUNDS 0.04% 896,639 SH Aug. 19, 2026 Daily
TILT · FlexShares Trust 0.02% 4,212 NS July 31, 2026 N-PORT
VTI · VANGUARD INDEX FUNDS 0.01% 2,482,796 SH Aug. 19, 2026 Daily
VTHR · VANGUARD SCOTTSDALE FUNDS 0.01% 6,117 SH Aug. 19, 2026 Daily
ITOT · iShares Trust 0.01% 103,097 SH Sept. 11, 2026 Daily
IWV · iShares Trust 0.01% 20,075 SH Sept. 11, 2026 Daily
PTH · Invesco Exchange-Traded Fund Trust 0.00% 91 SH Oct. 2, 2026 Daily
ISCB · iShares Trust · 3,478 SH Sept. 11, 2026 Daily
ISCV · iShares Trust · 10,938 SH Sept. 11, 2026 Daily
SMLF · iShares Trust · 37,682 SH Sept. 11, 2026 Daily
SMMV · iShares Trust · 1,644 SH Sept. 1, 2026 Daily

SYRE Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside

21
rating · 23 analysts BUY
Median target $121.00 +29.8%
11 47.8% Strong Buy
10 43.5% Buy
2 8.7% Hold
0 0.0% Sell
0 0.0% Strong Sell

12-Month Price Target

13 analysts · 2026-09-30

Mean target $120.08 +28.9%

← Below all targets Current price $93.19
Low$97.00 Mean$120.08 High$130.00

Peer comparison (GICS sub-industry) Key metrics vs sector peers

22

FY basis, prices as of each company's last fiscal year-end close.

Ticker Market Cap P/E Rev YoY Net Margin ROE Gross Margin
SYRE $2.56B 10.1 -62.0% · -26.5% ·
KYMR $6.33B -21.1 -16.7% -794.0% -24.4% ·
PCVX $6.05B -8.2 · · -26.6% ·
TGTX $4.63B 10.8 87.3% 72.6% 96.7% ·
PRAX $7.43B -21.9 249.5% · -47.3% ·
CAI $7.62B -8.4 97.0% -8.4% -13.2% ·
IONS $12.92B -33.2 · · -68.1% ·
IMVT $5.07B -9.0 229.2% · -73.7% ·

Latest News Recent headlines mentioning this company

23
Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools Nasdaq · 6 months, 2 weeks ago

My Metrics Your personal watchlist — selected rows from Full Fundamentals

26

Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.

Your selection is saved and follows you across all tickers.

Source: SEC 10-Q filed Aug 4, 2026